VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab. This analysis compared histologic outcomes.
VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab. This analysis compared histologic outcomes.